Medtronic

2348 articles with Medtronic

• Medtronic Announces Pricing of $2.0 Billion of Senior Notes

  3/23/2023

  Medtronic plc announced that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A., has priced an offering of $1,000,000,000 principal amount of 4.25% senior notes due 2028 and $1,000,000,000 principal amount of 4.50% senior notes due 2033.

• Medtronic to boost AI innovation with new platform introduction

  3/22/2023

  Medtronic plc announced Cosmo Pharmaceuticals and NVIDIA plan to integrate NVIDIA's AI technologies into the GI Genius™ intelligent endoscopy module — the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer.

• Medtronic and NVIDIA Collaborate to Build AI Platform for Medical DevicesIntegrating NVIDIA Technology Into Medtronic’s Real-Time AI Endoscopy Device to Help Improve Patient Care and Outcomes

  3/21/2023

  GTC—NVIDIA today announced that it is collaborating with Medtronic, the world’s largest healthcare technology provider, to accelerate the development of AI in the healthcare system and bring new AI-based solutions into patient care.

• Medtronic receives CE Mark approval for Affera™ Mapping and Ablation System to treat atrial arrhythmias

  3/15/2023

  Medtronic (NYSE:MDT) announced today that it has received CE (Conformité Européenne) Mark for the Affera™ Mapping and Ablation System, which includes the Sphere-9™ Catheter and the Affera™ Prism-1 Mapping Software.

• Medtronic named one of World's Most Ethical Companies

  3/13/2023

  Medtronic plc, a global leader in healthcare technology, has been recognized by Ethisphere, a leader in defining and advancing the standards of ethical business practices, as one of the 2023 World's Most Ethical Companies.

• Medtronic PulseSelect PFA System demonstrates impressive results in landmark PULSED AF global IDE trial

  3/6/2023

  Medtronic plc (NYSE: MDT) today announced that its PulseSelect™ Pulsed Field Ablation (PFA) System exceeded its safety performance goal, with an adverse event rate of 0.7%, one of the lowest adverse event rates of any prior U.S. FDA Investigational Device Exemption (IDE) trial for atrial fibrillation (AF) ablation or any multi-center PFA study.

• Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2023

  3/2/2023

  The board of directors of Medtronic plc on Thursday, March 2, 2023, approved the fiscal year 2023 fourth quarter cash dividend of $0.68 per ordinary share, representing an 8% increase over the prior year.

• Medtronic Executive Vice President and CFO Karen Parkhill to speak at Cowen healthcare conference

  2/27/2023

  Medtronic plc, a global leader in healthcare technology, announced it will participate in the 43rd annual Cowen healthcare conference on Monday, March 6, 2023.

• MiniMed™ 780G system demonstrates superiority over multiple daily injections with CGM for type 1 diabetes management at one-year in ADAPT study

  2/24/2023

  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced one-year data from the ADAPT study (n=82), the first multi-national randomized controlled study comparing the performance of the MiniMed™ 780G advanced hybrid closed loop system1 (AHCL) against multiple daily injections (MDI) of insulin with an intermittently scanned CGM (isCGM).

• Medtronic reports third quarter fiscal 2023 financial results

  2/21/2023

  Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2023, which ended January 27, 2023.

• Medtronic Receives CE Mark for Extravascular Defibrillator System That Treats Abnormal Heart Rhythms

  2/17/2023

  Medtronic plc has received CE Mark for the Aurora EV-ICD™ MRI SureScan™ and Epsila EV™ MRI SureScan™ defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest.

• Medtronic to announce financial results for its third quarter of fiscal year 2023

  2/14/2023

  Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of fiscal year 2023 on Tuesday, February 21, 2023.

• Medtronic LINQ Insertable Cardiac Monitor detects 10 times more atrial fibrillation in ischemic stroke patients at three years compared to standard of care

  2/8/2023

  Medtronic (NYSE: MDT) today announced late-breaking clinical data from the STROKE AF clinical study, which showed large and small vessel disease stroke patients had a 10-fold increase in AF detection with the Reveal LINQ™ insertable cardiac monitor (ICM) at three years compared to patients randomized to standard of care who did not receive continuous, long-term monitoring.

• Bronwyn Brophy is appointed new CEO of Vitrolife AB (publ)

  2/1/2023

  Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson.

• Medtronic recommends rejection of below-market mini-tender offer by TRC Capital Investment Corporation

  1/26/2023

  Medtronic plc recently became aware that TRC Capital Investment Corporation has made an unsolicited mini-tender offer to purchase up to 1,500,000 Medtronic ordinary shares, representing approximately 0.1% of the company's outstanding ordinary shares.

• Medtronic named one of America's Most JUST Companies by JUST Capital and CNBC

  1/10/2023

  Medtronic plc, a global leader in healthcare technology, has been named to the 2023 Rankings of America's Most JUST Companies by JUST Capital, along with media partner CNBC, for its commitment to serving its employees, customers, communities, the environment, and shareholders.

• Acutus Medical Achieves EU MDR Submission Milestone in Sale of Left-Heart Access Portfolio to Medtronic

  12/21/2022

  Acutus Medical, Inc. today announced that the Company has achieved the second milestone under the asset purchase agreement with Medtronic of its left-heart access portfolio with the submission for CE Mark of this portfolio under European Union (EU) Medical Device Regulations (MDR).

• Medtronic announces first patient enrolled in U.S. clinical trial for Hugo™ robotic-assisted surgery system

  12/15/2022

  Medtronic plc today announced the first patient enrolled in the Expand URO U.S. clinical trial for the Hugo™ robotic-assisted surgery.

• Medtronic Named as a Leading Sustainability Company - December 15, 2022

  12/14/2022

  Medtronic plc today announced its continued inclusion in the Dow Jones Sustainability World Index (DJSI) as one of the world's leading companies for sustainability.

• Medtronic announces cash dividend for third quarter of fiscal year 2023

  12/8/2022

  The board of directors of Medtronic plc on Thursday, December 8, 2022, approved the fiscal year 2023 third quarter cash dividend of $0.68 per ordinary share, representing an 8% increase over the prior year.